Scinai Immunotherapeutics (SCNI) Stock Statistics & Valuation Metrics

Scinai Immunotherapeutics has a market cap or net worth of $1.02M. The enterprise value is $8.60M.

Scinai Immunotherapeutics has 933,679 shares outstanding. The number of shares has decreased by -2.65% in one year.

Scinai Immunotherapeutics’s return on equity (ROE) is 0.00 and return on invested capital (ROIC) is 0.00%.

The current PE Ratio of Scinai Immunotherapeutics is 0.3. Scinai Immunotherapeutics’s PEG ratio is -0.00563.

In the last 12 months, Scinai Immunotherapeutics had revenue of 658.00K and earned 4.80M in profits. Earnings per share was 6.00.

In the last 12 months, operating cash flow was -5.69M and capital expenditures -16.00K, giving a free cash flow of -5.71M billion.

Scinai Immunotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Scinai Immunotherapeutics upcoming earnings date is Nov 26, 2025, TBA (Confirmed).

Scinai Immunotherapeutics as a current ratio of 0.00, with Debt / Equity ratio of 12.27%

In the past 12 months, Scinai Immunotherapeutics has paid 0.00 in taxes.

Scinai Immunotherapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of 0.00.

Scinai Immunotherapeutics has $989.00K in cash and marketable securities with $2.36M in debt, giving a net cash position of -$1.37M billion.

Gross margin is -46.74%, with operating margin of -1312.77%, and net profit margin of 728.88%.

The average price target for Scinai Immunotherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―